CAJ | 학술논문

目的：观察托泊替康联合顺铂治疗广泛期小细胞肺癌临床疗效及毒性反应。方法回顾性分析我科2010年1月至2012年6月收治的68例经病理证实的广泛期小细胞肺癌患者,其中 TC 组(托泊替康/顺铂)36例,21例为初治患者,15例为复治患者,EP 组(依托泊苷/顺铂)32例,均为初治患者。结果68例患者均可评价疗效,TC 组一线治疗有效率明显高于二线治疗组(χ2=0.461,P =0.006),与 EP 组差异无统计学意义(χ2=0.874,P =0.553)。TC 组一线治疗患者与 EP 组患者生存期差异无统计学意义(P =0.847),显著长于二线治疗患者(P =0.021)。不良反应主要为骨髓抑制、消化道反应及脱发。结论托泊替康联合方案治疗广泛期小细胞肺癌安全有效。
목적：관찰탁박체강연합순박치료엄범기소세포폐암림상료효급독성반응。방법회고성분석아과2010년1월지2012년6월수치적68례경병리증실적엄범기소세포폐암환자,기중 TC 조(탁박체강/순박)36례,21례위초치환자,15례위복치환자,EP 조(의탁박감/순박)32례,균위초치환자。결과68례환자균가평개료효,TC 조일선치료유효솔명현고우이선치료조(χ2=0.461,P =0.006),여 EP 조차이무통계학의의(χ2=0.874,P =0.553)。TC 조일선치료환자여 EP 조환자생존기차이무통계학의의(P =0.847),현저장우이선치료환자(P =0.021)。불량반응주요위골수억제、소화도반응급탈발。결론탁박체강연합방안치료엄범기소세포폐암안전유효。
Objective To study the efficacy and adverse effects of combined chemotherapy of topotecan and cisplatin in treatment of extensive stage small-cell lung cancer.Methods The clinicopathologic data of 68 patients with extensive stage small-cell lung cancer proved by pathology in our department from January 2010 to June 2012 were analyzed.21 patients were assigned to intravenous topotecan with cisplatin in first-line,1 5 patients were assigned to intravenous topotecan with cisplatin in second-line,32 patients were assigned to intravenous etoposide with cisplatin in first-line.Results The effective rate in TC group in first-line was significantly higher than that in second-line (χ2 =0.461,P =0.006).There was no statistical significance in the effective rate between TC group in first-line and EP group (χ2 = 0.874,P = 0.553 ).There was no statistical significance in overall survival between TC group in first-line and EP group (P =0.847).The overall survival in TC group in first-line was longer than that in second-line (P = 0.021 ).The main adverse reactions were bone marrow suppression, gastrointestinal reactions and alopecia.Conclusions Combined chemotherapy of topotecan and cisplatin is effective for extensive stage small-cell lung cancer patients,drug-related toxicities are tolerable.